| Biomarker ID | 557 |
| PMID | 20977276 |
| Year | 2011 |
| Biomarker | Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score 6 Vs Gleason Score 8 and above |
| Type of Biomarker | Prognostic |
| Cohort | 46 patients were chosen for the study such that 23 had a gleason score of 6 and 23 had a score of 8 or higher. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Two-Dimensional Differential in Gel Electrophoresis (2-D DIGE) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |